Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Vehicle Recompete: Idc 75F40122D00014

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract, identified as Idc vehicle 75F40122D00014, is a small business set-aside managed by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services. It has a ceiling value of $65,010,000 with an ordering period extending through September 14, 2027. The contract supports the FDA’s Center for Tobacco Products (CTP), specifically the Office of Compliance and Enforcement (OCE), which regulates tobacco products, manufacturers, and retailers to ensure compliance with federal laws. Although currently there are no active task orders under this vehicle, it has supported significant work previously, including a major task order for the processing of retailer compliance check inspection data valued at over $6.6 million awarded to MPF-ZAI Solutions LLC. The contract involves services that broadly cover compliance and enforcement functions related to tobacco control, with an emphasis on data management and regulatory oversight. It is classified as a full recompete vehicle under NAICS code 541611 and is designed exclusively for small business participation.

General Info

Small business contract by FDA for tobacco product compliance, $65 million ceiling, until 2027.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant SvcsView Agency

NAICS

541611 - Administrative Management and General Management Consulting ServicesView NAICS

Place of Performance

Not specified

Set-Aside

SBA

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

pre-forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Idc vehicle 75F40122D00014 ordering period ends 2027-09-14T00:00:00.000Z. 0 active task orders valued at $0.
The fda center for tobacco product's (ctp), office of compliance and enforcement (oce) has the authority to regulate tobacco products, manufacturers, and retailers. Oce regulates tobacco products, manufacturers, and retailers through a variety o Original Solicitation: 75F40121R00003 IDV Ceiling: $65,010,000 Set-Aside: Small business set aside - total Contracting Office: FDA Office Of Acq Grant Svcs Agencies: Department of Health and Human Services Classification: full-recompete (Confidence: high - 85/100)
Top task orders by value: - PROCESSING OF RETAILER COMPLIANCE CHECK INSPECTION DATA AND ASSOCIATED DOCUMENTS ($6,628,680.8) - MPF-ZAI SOLUTIONS LLC

Similar Contracts

Same NAICS industry code

NAICS: 541611
New
Federal
U.S.-India Technology Cooperation for Innovation growth workshop series
Solicitation # 191N6026Q0006-PR16144890
The U.S. Consulate General Chennai has issued solicitation 191N6026Q0006-PR16144890 for a firm fixed price purchase order to conduct the U.S.-India Technology Cooperation for Innovation Growth Workshop Series. This specialized program is designed to foster cooperation by focusing on U.S. intellectual property protection and market access principles, targeting approximately 100 participants from Indian academic technology hubs, legal professionals, and private-sector stakeholders. Key deliverables include a comprehensive gap report, three quarterly virtual workshops, and a culminating in-person workshop, all to be completed within 12 months of contract signing. The contractor is expected to provide subject-matter experts to lead these sessions and must ensure all program materials clearly acknowledge U.S. Government or Department of State support using specific branding and flag requirements. The government intends to award the contract to the lowest priced, technically acceptable offeror that demonstrates a satisfactory record of past performance, financial capability, and technical expertise. Mandatory requirements for submission include a completed Technical Evaluation Form and compliance with all solicitation sections. While SAM registration is mandatory for orders exceeding $40,000, overseas offerors without active registration must provide specific identification details as outlined in FAR 52.204-90. Technical queries must be submitted by August 18, 2026, and final quotations must be emailed to the Contracting Officer, Mr. Seth A. Burchett, no later than August 27, 2026, at 03:00 p.m. IST. The contractor must also adhere to strict cybersecurity, safety, and labor standards, including compliance with the Defense Base Act for workers' compensation.
American Consulate Chennai

POSTED

about 7 hours ago

DEADLINE

in 3 days
View Details
NAICS: 541611
New
Federal
Pandemic Plan Preparedness Evaluation Services
Solicitation # IHS1548449
The Indian Health Service (IHS) is seeking a single Firm-Fixed-Price contract for professional consulting services to evaluate and stress-test the 2025 IHS Pandemic Preparedness Plan. The objective is to enhance pandemic readiness through a four-task scope of work: discovery and analysis, the execution of two web-based simulation exercises, the development of a comprehensive After-Action Report with a corrective-action matrix, and a final findings dissemination meeting for IHS leadership. All work must be performed within the United States, primarily off-site and virtually, with a period of performance extending through July 31, 2027. This opportunity is a 100 percent set-aside for Indian Economic Enterprises (IEEs) that are also small business concerns under the Buy Indian Act. Eligible offerors must submit a signed IEE Representation Form to avoid being ineligible for award and must ensure that at least 50 percent of personnel costs are expended for IEE employees. The evaluation will be conducted via a tradeoff process where non-price factors—including technical approach, staffing and management, and past performance—are significantly more important than price. Key deliverables must comply with Section 508 accessibility requirements and be subject to a comprehensive Quality Control Plan. Quotes are due by 2:00 p.m. Eastern Time on August 14, 2026, and must be submitted in two separate volumes: a technical quote limited to 15 pages and a price quote containing administrative documentation.
Omas Strategic Buying Center - Professional Services

POSTED

about 7 hours ago

DEADLINE

in 2 days
View Details
NAICS: 541611
New
Federal
2024 & 2025 Estimates of WIC Eligibility and Program Reach
Solicitation # 12319826Q5007
The USDA Food and Nutrition Administration is soliciting quotations for a firm-fixed-price contract to produce detailed estimates of WIC eligibility and program reach for calendar years 2024 and 2025. The scope of work requires the contractor to generate eligibility counts, rates, coverage, and participation rates at national, regional, state, county, and Congressional district levels. Key deliverables include a full technical report for 2024/2025, a brief national report for 2024, analytic data files, and interactive online graphics. All analyses must be accompanied by the complete data, code, and documentation necessary for replication, and all public-facing materials must be 508-compliant. The period of performance is 18 months from the date of award. This procurement will be conducted under full and open competition, with the award method being Highest Rated Technically Acceptable. Evaluation will be based on three descending factors: Technical Approach, Past Performance, and Price. Offerors must submit proposals in three distinct volumes: Technical Capability, Past Performance, and Price. The technical volume is subject to strict formatting and page limits, while the past performance evaluation will assess the likelihood of success based on the recency and relevance of prior analytical or research work. The contract includes specific requirements regarding key personnel resumes, staffing plans for security clearances, and strict adherence to federal anti-discrimination laws and executive orders. Quotations must be submitted by the specified deadline via SAM.gov or email as directed in the solicitation.
USDA Food And Nutrition Administration

POSTED

about 7 hours ago

DEADLINE

in 7 days
View Details

More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

Same awarding agency

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details